Clinical trial design for endovascular ischemic stroke intervention

Area of Science:

• Neurology
• Clinical Trials
• Medical Research

Background:

• Randomized, double-blinded, placebo-controlled trials are crucial for advancing clinical practice.
• Acute ischemic stroke (AIS) therapy trials face challenges in standardization, enrollment, patient selection, and bias.
• Logistical, financial, and data monitoring issues also impact AIS clinical trial conduct.

Purpose of the Study:

• To review clinical trial designs for acute ischemic stroke (AIS) therapy.
• To identify challenges inherent in AIS clinical trial methodologies.
• To propose innovative designs and recommendations for overcoming these limitations.

Main Methods:

• Review of selected randomized and single-arm prospective AIS trial designs.
• Analysis of key clinical trial elements and their associated challenges.
• Discussion of innovative designs and recommendations for improvement.

Main Results:

• AIS therapy trials encounter specific challenges including ethical considerations, enrollment rates, outcome measures, treatment time windows, efficacy, safety, and operator variability.
• Proposed improvements include lead-in phases, refined patient and outcome measure selection, various control groups (historical, concurrent, hybrid), open data access, and Bayesian methods.
• Open data can enable predictive modeling, reducing costs and optimizing resource allocation. Collaborative networks and adaptive trial designs (self-learning, self-correcting) can enhance efficiency.

Conclusions:

• Randomized clinical trial design for AIS endovascular therapy presents significant challenges.
• Implementing lead-in phases, meticulous patient selection, novel outcome measures, and appropriate control groups are essential.
• Adopting advanced clinical trial designs can improve the conduct, validity, and outcomes of future AIS research.